Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanner, C. M.
Right arrow Articles by Klawans, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanner, C. M.
Right arrow Articles by Klawans, H. L.
NEUROLOGY 1985;35:918
© 1985 American Academy of Neurology

Pergolide mesylate

Lack of cardiac toxicity in patients with cardiac disease

Caroline M. Tanner, MD, Ramesh Chhablani, MD, Christopher G. Goetz, MD and Harold L. Klawans, MD

Departments of Neurological Sciences (Drs. Tanner, Goetz, and Klawans) and Medicine (Dr. Chhablani), Rush-Preshyterian-St. Luke's Medical Center, Chicago, IL.

In a 12-month open-label trial, pergolide mesylate was administered in doses with antiparkinsonian efficacy to six patients with stable heart disease. Cardiac status did not worsen in any patient. Parkinson's disease improved in all patients. Pergolide is a safe and effective therapy for Parkinson's disease, even in patients with heart disease.

Address correspondence and reprint requests to Dr. Tanner, Rush-Preshyterian-St. Luke's Medical Center, Neurological Sciences, 1753 West Congress Parkway, Chicago, IL 60612.

Supported in part by grants from the United Parkinson Foundation, Boothroyd Foundation, Chicago, IL, and Eli Lilly Company, Indianapolis, IN. Dr. Goetz is the recipient of an NINCDS Teacher-Investigator Award

Presented in part at the thirty-fourth annual meeting of the American Academy of Neurology, Washington, DC, April 1982.

Accepted for publication October 3, 1984.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.